Related Experiment Video
Updated: May 13, 2026

07:15
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
An algorithm for candidate sequencing in non-dystrophic skeletal muscle channelopathies
Tai-Seung Nam1, Christoph Lossin, Dong-Uk Kim
1Department of Neurology, The Brain Korea 21 Project, Chonnam National University Medical School, 8 Hakdong, Donggu, Gwangju 501-757, Korea.
Journal of Neurology
|March 5, 2013
Summary
This study details human skeletal muscle channelopathies (HSMCs), linking specific genetic mutations to clinical symptoms. An online tool, CGPS, aids in differential diagnosis and personalized treatment for these rare genetic disorders.
Area of Science:
- Genetics
- Neurology
- Molecular Biology
Background:
- Human skeletal muscle channelopathies (HSMCs) are a group of rare, inherited disorders affecting muscle function due to ion channel gene mutations.
- These conditions often present with similar clinical features, complicating accurate diagnosis.
- Understanding the genotype-phenotype correlations is crucial for effective management.
Purpose of the Study:
- To comprehensively map the phenotypic spectrum of HSMCs.
- To establish clear genotype-phenotype correlations for key HSMC-associated genes (SCN4A, CACNA1S, KCNJ2, CLCN1).
- To develop a diagnostic tool for differential diagnosis of HSMCs.
Main Methods:
- Systematic collection and analysis of genotype and phenotype data from over 500 published HSMC studies.
- Development of a symptom-based, binary decision flow algorithm to predict genetic origin.
- Implementation of the algorithm into an online diagnostic tool (CGPS).
Main Results:
- Identified strong correlations between specific clinical features and mutations in SCN4A, CACNA1S, KCNJ2, and CLCN1 genes.
- The developed algorithm accurately predicts the genetic basis of HSMCs (0.88-0.93 accuracy).
- The CGPS online tool provides efficient, symptom-guided navigation for diagnosis.
Conclusions:
- The CGPS tool facilitates accurate and targeted genetic screening for HSMCs.
- Accurate diagnosis enables tailored pharmacotherapy based on the identified molecular basis.
- This approach improves clinical practice for managing HSMC patients.

